Identification of unique subtype-specific interaction features in Class II zinc-dependent HDAC subtype binding...

Area of Science:

• Biochemistry and Molecular Biology
• Medicinal Chemistry
• Computational Drug Discovery

Background:

• Zinc-dependent histone deacetylase (ZnHDAC) subtypes are implicated in cancer, but current pan-HDAC inhibitors cause side effects due to lack of specificity.
• Targeting specific ZnHDAC subtypes offers a promising strategy for developing more effective anticancer drugs with reduced toxicity.

Purpose of the Study:

• To decipher the unique interaction features of six ZnHDAC subtypes, focusing on Class II, to enable the rational design of subtype-specific inhibitors (SSIs).
• To identify distinct pharmacophoric patterns and binding site residue interactions for each ZnHDAC subtype.

Main Methods:

• Utilized homology modeling, molecular docking, pharmacophore analysis, and molecular dynamics (MD) simulations to analyze experimental data.
• Docked validated SSIs and approved pan-HDAC inhibitors (PHIs) to multiple ZnHDAC conformations and estimated binding energies.
• Compared binding site sequences, structures, and interaction patterns to identify subtype-specific features.

Main Results:

• Identified distinct pharmacophoric patterns and unique binding site residue interactions for each ZnHDAC subtype, despite high sequence similarity.
• Observed specific interactions, such as E329 for HDAC4, S904 for HDAC5, W496/S563/I569 for HDAC6, M793 for HDAC9, and E302 for HDAC10.
• Demonstrated that SSI features, including functional groups and sub-pocket occupancy, influence binding site residue orientation.

Conclusions:

• Unique interaction features and pharmacophoric patterns exist for each ZnHDAC subtype, particularly Class II.
• These identified features provide a foundation for the rational design of novel, subtype-specific ZnHDAC inhibitors for improved cancer therapy.